Ki67 correlation with biochemical failure and disease recurrence after HDR-BT treatment for prostate cancer is an area which is understudied and could prove valuable in providing a more accurate risk stratification and identifying potential therapeutic targets. This evidence concerns the gene MKI67 and prostate cancer.